title: Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration.
abstract: The purpose of this article is to describe functional and morphological short-term results in patients with exudative age-related macular degeneration (AMD) of all subtypes, treated with intravitreal bevacizumab versus intravitreal ranibizumab. This was a retrospective case-controlled series of 30 patients treated with intravitreal bevacizumab and 30 patients treated with intravitreal ranibizumab for exudative AMD. All patients received three initial injections every 4 weeks. Best corrected visual acuity (BCVA) as well as greatest linear dimension (GLD) of the CNV in fluorescein angiography and central retinal thickness (CRT) in optical coherence tomography (OCT) were monitored 2-4 months after last injection. BCVA stabilized and slightly increased from logMAR 0.74 to 0.62 in the bevacizumab group, and from logMAR 0.76 to 0.58 in the ranibizumab group (P < 0.05 for each group). No statistical difference was seen between both groups at any time-point. CRT was significantly reduced in both groups at last follow-up. In contrast, GLD did not change significantly. Patients with exudative AMD of all subtypes benefit from intravitreal anti-VEGF injections. No significant difference between bevacizumab and ranibizumab is seen in the short-term follow-up.
authors.affiliation: University Eye Clinic, Franz-Josef-Strauss Allee 11, 93051, Regensburg, Germany. gamulescu@eye-regensburg.de
authors.forename: Maria-Andreea
authors.initials: MA
authors.lastname: Gamulescu
authors.forename: Viola
authors.initials: V
authors.lastname: Radeck
authors.forename: Bruno
authors.initials: B
authors.lastname: Lustinger
authors.forename: Bianca
authors.initials: B
authors.lastname: Fink
authors.forename: Horst
authors.initials: H
authors.lastname: Helbig
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D000069579:Ranibizumab; D012189:Retrospective Studies; D013997:Time Factors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab